Summary

Overview
Global gene prediction tool market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global gene prediction tool market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Basically, gene prediction involves identifying genes along the genome. The process of locating the areas of genomic DNA which encode genes is sometimes referred to as gene discovery. Genes that code for proteins, RNA, and other functional components like regulatory genes are included in this.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced software or services and boost the global gene prediction tool market. The respective innovative products includes the use of novel tools such as JIGSAW, GENEID for drug discovery.
Market Dynamics: Drivers & Restraints
Growing collaborations and initiatives
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for gene prediction tool owing to the rising research. Various product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On January 18, 2022, Thermo Fisher Scientific and Oncocyte Corporation have entered into a development and collaborative marketing arrangement for a pair distributed in vitro diagnostic (IVD) assessments on the Ion Torrent Genexus System. A precision diagnostics company, Oncocyte Corporation, improving patient outcomes by delivering clear insights that inform crucial decisions in the detection, management, and monitoring of cancer.
Additionally, on July 20, 2023, in order to develop epigenetic drugs using zinc finger proteins (ZFPs) for DNA recognition which is sequence-specific, a clinical-stage genomic medicine company, Sangamo Therapeutics, Inc., and Chroma Medicine, Inc., a genomic medicine company that invented single-dose epigenetic editing treatments, have entered into a research assessment, option, and license agreement.
Furthermore, the rising utilization of novel technology and software for the management of several diseases. Rising awareness among people and increasing research for innovative diagnostic or treatment product development will be a major factor driving the growth of the gene prediction tools market.
Limitations associated with the gene prediction tools
Recent reviews have brought attention to the fact that protein-coding genes are still difficult for automated genome annotation methods to appropriately identify. Significant amounts of genetic sequence divergence, the intricacy of eukaryotic exon mapping, the state of the draft genome assemblies, or variations from classical genetic traits could all be factors in this failure.
Therefore, it is crucial to compare the many gene prediction algorithms now in use in order to gauge their dependability, pinpoint the most promising tactics, as well as to stop the propagation of mistakes in protein databases.
For more details on this report - Request for Sample
Segment Analysis
The global gene prediction tool market is segmented based on component, method, application, end user and region.
Ab-Initio Prediction segment accounted for approximately 59% of market share
In the absence of an experimentally solved structure for a related or homologous protein, a technique known as ab initio prediction of protein structures can be used to ascertain the tertiary structure of a protein. This approach creates protein structure that is influenced by energy function. The difficult endeavor of predicting protein structures solely from sequence data and without the use of templates is known as ab initio prediction.
It is frequently broken down into two independent sub-problems: the method of exploring the conformational space and the scoring system that can discriminate native or native-like structures from non-native ones. A reliable scoring system that can always direct a search towards the native fold doesn't exist yet, and there is no universal search strategy that can provide a sizeable sample of near-natives. Pathway models integrate the search and the scoring function.
According to Briefings in Bioinformatics in 2021, a program called TSSFinder was used to describe the promoter sequences from Eukaryotic species. The initial transcription start site (TSS) prediction approach that uses a probabilistic model based on linear chain conditional random fields (LCCRFs) is TSSFinder, which was originally disclosed in the literature. TSSFinder may be tailored to new organisms and is more accurate than previously released tools.
Geographical Penetration
North America accounted for around 37% of market share in 2022
Due to the rising need for gene prediction tool in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for gene prediction tool.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of tool for research, and increase in biopharmaceutical or bioinformatics business establishment across the region are also contributing to the growth of gene prediction tool market share of this region. The market in this area is growing as people become more aware of various novel innovative tools. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global gene prediction tool market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for gene prediction tool in the U.S. United States have been proactive in executing several initiatives or researches, stimulating gene prediction tool demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene prediction tool market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for gene prediction tool. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global gene prediction tool market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for iinovative tools, like ab-initio prediction tools.
Key Developments
• On June 1, 2023, the new PrimateAI-3D artificial intelligence (AI) algorithm, developed by Illumina Inc., an innovator in DNA sequencing as well as array-based technologies, predicts disease-causing genetic variants in patients with unparalleled accuracy. Two papers outlining the development of the algorithm and its implementation to fifty thousand genomes in the United Kingdom Biobank cohort were published in Science on June 2 (issue 6648) with the results.
• On January 23, 2023, By incorporating game-changing evaluation speed to assess and comprehend whole exome sequencing (WES), whole genome sequencing (WGS), and large panel sequencing data, the bioinformatics division of QIAGEN, QIAGEN Digital Insights, improved QIAGEN CLC Genomics Workbench Premium, which removes the data-analysis obstacles of next-generation sequencing (NGS).
• On May 16, 2022, A no-cost program for the annotation, characterisation, and visualization of specific antibodies will be made available by Geneious Biologics. The Geneious Biologics antibody annotation's potency can be personally experienced by researchers thanks to the online free antibody sequence analysis tool.
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Softberry, Inc., Illumina, Inc., QIAGEN, GenScript, DNASTAR, BGI,Geneious, Sangamo Therapeutics and Takara Bio Inc..
Why Purchase the Report?
• To visualize the global gene prediction tool market segmentation based on component, method, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of gene prediction tool market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global gene prediction tool market report would provide approximately 69 tables, 66 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Component
3.2. Snippet by Method
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and initiatives
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Limitations associated with the gene prediction tools
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Component
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
7.1.2. Market Attractiveness Index, By Component
7.2. Software*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Services
7.3.1. Meglumine Antimoniate (Glucantim)
7.3.2. Similarity Based Searches
7.3.3. Ab-Initio Prediction
8. By Method
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
8.1.2. Market Attractiveness Index, By Method
8.2. Similarity Based Searches*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ab-Initio Prediction
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Drug Discovery *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Genetic Disorder Diagnosis
9.4. Biomedical Research
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Biotechnology and Life Science Companies
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Thermo Fisher Scientific Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Softberry, Inc.
13.3. Illumina, Inc.
13.4. QIAGEN
13.5. GenScript
13.6. DNASTAR
13.7. BGI
13.8. Geneious
13.9. Sangamo Therapeutics
13.10. Takara Bio Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us